Private equity firms have been investing in health care practices, with at least one report positing that 2022 was the second-best year in recent history.
That level of activity is attracting attention of federal regulators overseeing medical care, billing, and business arrangements of physicians and investors, said Jolie Apicella, JD, a partner in the health care practice group at the New York-based law firm Wiggin and Dana.
Previously Apicella served as an assistant United States attorney in the Eastern District of New York, where she served as chief of health care fraud. Now she also represents entities and their executive leaders before the U.S. Department of Health and Human Services Office of Inspector General, the U.S. Department of Justice (DOJ), and other federal and state government regulatory and compliance officials.
Apicella spoke with Medical Economics to share her insights about what physicians and investors should know about federal and state regulations over medicine and private equity investment. Read more.
